Stock Comparison

ECOR vs JNJ

electroCore, Inc. vs Johnson & Johnson

The Verdict

ECOR takes this one.

Winner

ECOR

electroCore, Inc.

2.5

out of 10

Risk Trap

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$79M

Market Cap

$557.1B

N/A

P/E Ratio

26.5

-44.1%

Profit Margin

21.8%

-235.8%

Return on Equity

26.3%

N/A

Debt-to-Equity

0.6

Aggressive

Overall Risk

Conservative

2.5

DVR Score

1.0

The Deep Dive

ECOR2.5/10

electroCore exhibits strong operational execution, evidenced by Q1 2026 revenue of $9.6M, representing a 42.64% YoY increase, and its gammaCore device addresses a vast market for headache disorders with patented, non-invasive technology. This market potential and product strength are compelling. However, these positives are severely undermined by critical financial distress. The company faces pers...

Full ECOR Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.